文献速递技术与安全PETCT

早期Al18F-成纤维细胞激活蛋白抑制剂-04 PET/CT扫描可行性的临床研究

A clinical study of the feasibility of early Al18F-fibroblast activation protein inhibitor-04 PET/CT scans.
PubMed 文献 · Br J Radiol · 2026-01-01

本研究纳入101例各类癌症患者,比较注射后15分钟与30分钟Al18F-FAPI-04 PET/CT显像,共检出560个病灶,两个时间点均能识别全部病灶。肿瘤SUVmax在两个时间点无显著差异,但30分钟时肝癌、淋巴瘤及多数转移灶的TBR更高。注射后15分钟即可完成FAPI-04扫描似乎是可行的。

要点

  • 注射后15分钟与30分钟Al18F-FAPI-04 PET/CT对全部560个病灶的检出率相当。
  • 30分钟时肝癌TBR 4.54高于15分钟时的4.14(P < .001),淋巴瘤TBR 4.88高于4.75(P = 0.043)。
  • 脑、肝、血池SUVmean在15至30分钟间快速下降,平均ΔSUVmean分别为-0.04、-0.07、-0.21(P < .001)。

核心结论

  • Al18F-FAPI-04 PET/CT在注射后15分钟与30分钟的肿瘤检出率和病灶摄取相当,肿瘤及背景摄取稳定且TBR持续较高,注射后15分钟即行FAPI-04扫描似乎是可行的。

研究设计与样本

  • 纳入101例各类癌症患者的临床研究,所有患者均接受注射后15分钟和30分钟两个时间点的Al18F-FAPI-04 PET/CT显像,以SUVmax、SUVmean和TBR评估示踪剂摄取。

关键影像表现/征象

  • 101例患者共检出560个病灶(实体瘤466个、血液系统肿瘤94个),两个时间点均识别全部病灶。
  • 注射后15至30分钟,脑、肝和血池的SUVmean快速下降,平均ΔSUVmean分别为-0.04、-0.07和-0.21(P < .001)。
  • 患者水平肿瘤病灶SUVmax在两个时间点无显著差异;病灶水平SUVmax基本一致,无统计学显著变化。

诊断标准与关键数值

  • 肝癌TBR在30分钟为4.54,高于15分钟的4.14(P < .001)。
  • 淋巴瘤TBR在30分钟为4.88,高于15分钟的4.75(P = 0.043)。
  • 多数转移性肿瘤病灶在30分钟观察到更高的TBR。

临床应用与阅片要点

  • 注射后15分钟与30分钟Al18F-FAPI-04 PET/CT对肿瘤病灶的检出和SUVmax评估相当,早期扫描似乎可行。
  • 肝癌、淋巴瘤及多数转移灶在30分钟TBR更高,阅片时需注意两个时间点TBR的差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: In this study, we systematically compared early Al18F-FAPI-04 imaging performed at 15 and 30 minutes post-injection in patients with various types of cancer to determine whether an early imaging scan can fulfil the criteria for clinical diagnosis.

METHODS: The cohort comprised 101 patients with various cancer diagnoses who underwent Al18F-FAPI-04 PET/CT imaging at 2 time points: 15 and 30 minutes post-injection. Tracer uptake was assessed using SUVmax, SUVmean, and TBR.

RESULTS: In total, 560 lesions were detected among 101 patients (solid tumours: 466; haematologic neoplasms: 94), all of which were identified at both imaging time points. Between 15 and 30 minutes post-injection, the SUVmean of various organs decreased rapidly (the average ΔSUVmean for the brain, liver, and blood pool was -0.04, -0.07, and -0.21, respectively; P < .001). At the per-patient level, there was no significant difference in the SUVmax of tumour lesions. On a per-lesion basis, SUVmax remained largely consistent, showing no statistically significant variation. However, a higher TBR at 30 minutes was observed in liver cancer (4.14 vs. 4.54; P < .001), lymphoma (4.75 vs. 4.88; P = 0.043), and most metastatic tumour lesions.

CONCLUSIONS: Al18F-FAPI-04 PET/CT imaging demonstrated remarkably stable tumour and background uptake with consistently high TBR. Both the tumour detection rate and lesion uptake were comparable at 15 and 30 minutes post-injection. Therefore, performing a FAPI-04 scan as early as 15 minutes post-injection appears feasible.

ADVANCES IN KNOWLEDGE: Al18F-FAPI-04 PET/CT enables early imaging, significantly reducing patient waiting times.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Han W, Lyu Z, et al. A clinical study of the feasibility of early Al18F-fibroblast activation protein inhibitor-04 PET/CT scans. Br J Radiol. 2026. PMID: 41212205. doi:10.1093/bjr/tqaf274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。